Opportunity
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks effective targeted therapies, leaving chemotherapy as the primary treatment option. However, chemotherapy is often associated with high toxicity and limited efficacy, leading to poor patient outcomes. TNBC accounts for approximately 15-20% of all breast cancer cases and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. The lack of these receptors means that hormonal therapies and HER2-targeted treatments are ineffective, creating a significant unmet medical need. Moreover, TNBC tends to have a higher recurrence rate and worse prognosis compared to other breast cancer subtypes. The overexpression of the NIP7 gene, a critical regulator of ribosome biogenesis, has been identified as a key driver of TNBC progression. NIP7 overexpression correlates with poor survival rates in TNBC patients, making it a promising therapeutic target. Currently, there are no approved drugs specifically targeting NIP7, highlighting a critical gap in TNBC treatment strategies.
Technology
This patent introduces a novel CRISPR/Cas9-based gene-editing approach to inhibit NIP7 expression in TNBC cells. The technology utilizes guide RNA (gRNA) molecules designed to target and silence the NIP7 gene, thereby disrupting its role in ribosome biogenesis and cancer cell proliferation. The gRNA molecules (SEQ ID NO.1 and SEQ ID NO.2) are delivered via lentiviral vectors, which efficiently transduce TNBC cells and induce NIP7 knockout. The lentivector particles also incorporate a doxycycline-inducible promoter (e.g., H1 promoter) to control gRNA expression and a sequence encoding the Cas9 protein, which acts as molecular scissors to cleave the NIP7 gene. Preclinical studies demonstrate that NIP7 knockout significantly reduces TNBC cell proliferation in both 2D and 3D cultures, inhibits colony formation, and induces apoptosis. In vivo experiments further confirm that NIP7 depletion markedly suppresses tumor growth in mouse xenograft models. This approach offers a highly specific and potent alternative to conventional chemotherapy, with the potential for fewer side effects.
Advantages
- High Specificity: Targets NIP7, a gene overexpressed in TNBC but not in normal tissues, minimizing off-target effects.
- Potent Efficacy: Demonstrated significant inhibition of TNBC cell proliferation and tumor growth in preclinical models.
- Reduced Toxicity: Avoids the systemic toxicity associated with chemotherapy.
- Versatile Delivery: Lentiviral vectors ensure efficient and stable gRNA delivery to cancer cells.
- Combination Potential: Can be used alongside PI3K/Akt inhibitors, CDK4/6 inhibitors, or immune checkpoint inhibitors for enhanced therapeutic effects.
Application
- TNBC Treatment: Primary application for triple-negative breast cancer patients with NIP7 overexpression.
- Combination Therapy: Potential use with chemotherapy or targeted agents (e.g., PI3K/Akt inhibitors) to improve outcomes.
- Diagnostic Tool: NIP7 expression levels could serve as a biomarker for TNBC prognosis and treatment selection.
- Research Tool: Facilitates study of NIP7’s role in ribosome biogenesis and cancer progression.
